RxDoctor Payments Data

Asad Sheikh, MD

Interventional Cardiology · McHenry, ILNPI 1588759815

Payments from drug & device makers

What this record shows

19 manufacturers reported payments, led by Medtronic at 45.3% of the total. 2025 is the largest year on record at $4,134, 9.4 times the $440 reported in 2019.

$10,526in general payments, 2019–2025

Across 176 payments — averaging $59.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Edwards Lifesciences$2K
  • Boston Scientific$1K
  • Medical Device Business Services, Inc.$770
  • Abbott$592
  • Stryker$238
  • plus $919 from 13 others
$10,235in research payments, 2019–2025

Across 5 payments — averaging $2047.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • W. L. Gore & Associates, Inc.$10K
  • Abbott$10

What the payments were for

  • Travel & lodging$5,30550%
  • Food & beverage$5,22150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,526 in reported general payments places this provider in the 55th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois →

Medicare billing

Part B allowed, 2024
$280,197
Medicare patients
2,984
Services billed
5,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$132,179
XareltoRivaroxaban21$25,285
BrilintaTicagrelor22$17,400
ClopidogrelClopidogrel Bisulfate150$1,935
Metoprolol Succinate99$1,736
Atorvastatin Calcium122$1,165
Carvedilol77$951
Metoprolol Tartrate83$789
Bumetanide18$761
Losartan Potassium58$683
Amlodipine Besylate92$666
Rosuvastatin Calcium30$608
Digoxin16$433
Isosorbide Mononitrate ErIsosorbide Mononitrate30$394
Pravastatin Sodium28$374

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in McHenry

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →